Skip to Content

A new phase 3 trial shows significantly prolonged overall survival for patients with AML

Clinical and biological markers associated with long-term survival for patients with acute myeloid leukemia in remission after chemotherapy in the QUAZAR AML-001 trial of oral AZACITIDINE.

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top